Is lipoatrophy associated with vascular dysfunction?

HIV Treatment Bulletin - Vol. 8, No. 8/9, August-September 2007

Michael Dube, for NATAP.org

Lipoatrophy is associated with a variety of adverse cardiovascular risk factors such as dyslipidemia and insulin resistance, but as yet there has been no good evidence that cardiovascular event rates are higher or vascular dysfunction is greater among those with lipoatrophy or lipohypertrophy. The group from Indiana University presented data on a large cross-sectional study of vascular endothelial function measured by brachial artery reactivity by ultrasound that included detailed body composition analysis by DEXA and CT methods in 96 subjects in clinical HIV care.

Half were ART-naïve, and among the treated subjects 53% were on PI. Interestingly, vascular endothelial function tended to be worse among those subjects on ART with the lowest levels of limb fat compared to those with higher levels - suggesting a mechanism that somehow lipoatrophy (perhaps mediated by metabolic dysfunction) could lead to more cardiovascular disease. There was no relationship between visceral fat and endothelial function, and PI use also did not appear to be related to worse endothelial function by brachial artery reactivity testing.

Although PI use has generally been considered to be associated with endothelial dysfunction, early studies included many subjects on indinavir, which to date is the only PI conclusively shown to directly induce endothelial dysfunction. Another presentation at this meeting in ART-naïve subjects reported that with initiation of ART, endothelial dysfunction improved even if subjects received the PI lopinavir-ritonavir. So, it is possible with currently-used PIs, that endothelial dysfunction is not a directly drug-induced problem. Regardless, endothelial dysfunction does occur and presumably will contribute to increased cardiovascular events. The mechanism by which lower limb fat is associated with endothelial dysfunction clearly deserves further study, and perhaps we should be particularly vigilant about managing cardiovascular risk in our patients with lipoatrophy.

Ref: Dube et al. Relationship of body composition, antiretroviral use and HIV disease factors to endothelial dysfunction in HIV-infected subjects.

2007-08-10
IB070808-28

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.